Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease
- PMID: 22866900
- PMCID: PMC3449192
- DOI: 10.1186/1471-230X-12-102
Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease
Abstract
Background: Glycoprotein 2 (GP2) was discovered as the major autoantigen of Crohn's disease (CD)-specific pancreatic autoantibodies (PAB). We investigated anti-GP2 IgA and IgG antibodies as novel serological parameters in CD and assessed their association with distinct disease phenotypes.
Methods: Anti-GP2 and anti-Saccharomyces cerevisiae (ASCA) IgA and IgG were detected by ELISA employing recombinant human GP2 and phosphopeptidomannan, respectively and PAB by indirect immunofluorescence (IIF) in 271 sera, 169 with CD and 102 with ulcerative colitis (UC). As healthy controls 160 adult blood donors and 65 children were included.
Results: Anti-GP2 IgG and/or IgA were more prevalent in CD (51/169, 30.2%) than in UC (9/102, 8.9%) patients and in controls (9/225, 4%) (p < 0.001 respectively). ASCA IgG and/or IgA were present in 60/169 (35.5%) in CD and in 7/102 (6.9%) in UC patients (p < 0.001). CD patients with ileocolonic location (L3) showed a significantly higher prevalence of anti-GP2 and ASCA IgA and/or IgG (40/113 and 48/113, respectively; p < 0.05 for both comparisons), whereas CD patients with colonic location (L2) revealed a significantly diminished prevalence for these autoantibody specificities (2/32 and 5/32, respectively, p < 0.05 for both). Anti-GP2 IgG were significantly more prevalent in CD patients with stricturing behaviour (B2) and perianal disease (7/11, p < 0.02) and less prevalent in those with penetrating behaviour (B3) and perianal disease (4/31, p < 0.05). The occurrence of anti-GP2 IgA and/or IgG was significantly more prevalent in CD patients with age at diagnosis of ≤16 years (16/31, p < 0.009). Prevalence of one or more anti-GP2 or ASCA IgA and/or IgG was significantly higher in L3, B2, and A1 and lower in L2 (68/113, 27/41, 23/31, 6/32; p < 0.04, respectively).
Conclusions: Anti-GP2 IgG and IgA, constituting novel CD specific autoantibodies, appear to be associated with distinct disease phenotypes identifying patients at a younger age, with ileocolonic location, and stricturing behaviour with perianal disease.
Figures

Similar articles
-
Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease.Medicine (Baltimore). 2015 Oct;94(42):e1654. doi: 10.1097/MD.0000000000001654. Medicine (Baltimore). 2015. PMID: 26496271 Free PMC article.
-
Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease.Clin Chim Acta. 2011 Apr 11;412(9-10):718-24. doi: 10.1016/j.cca.2010.12.029. Epub 2010 Dec 31. Clin Chim Acta. 2011. PMID: 21195704
-
Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies.Clin Chem Lab Med. 2016 Feb;54(2):249-56. doi: 10.1515/cclm-2015-0376. Clin Chem Lab Med. 2016. PMID: 26351932
-
Glycoprotein 2 antibodies in Crohn's disease.Adv Clin Chem. 2013;60:187-208. doi: 10.1016/b978-0-12-407681-5.00006-4. Adv Clin Chem. 2013. PMID: 23724745 Review.
-
Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies.Autoimmun Rev. 2011 Dec;11(2):143-8. doi: 10.1016/j.autrev.2011.09.004. Epub 2011 Sep 29. Autoimmun Rev. 2011. PMID: 21983481 Review.
Cited by
-
Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease.Inflamm Bowel Dis. 2016 Nov;22(11):2648-2657. doi: 10.1097/MIB.0000000000000936. Inflamm Bowel Dis. 2016. PMID: 27753692 Free PMC article.
-
Precision medicine in inflammatory bowel disease.Precis Clin Med. 2023 Dec 18;6(4):pbad033. doi: 10.1093/pcmedi/pbad033. eCollection 2023 Dec. Precis Clin Med. 2023. PMID: 38638127 Free PMC article. Review.
-
The Novel Crohn's Disease Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of Disease.Gastroenterol Res Pract. 2013;2013:683824. doi: 10.1155/2013/683824. Epub 2013 May 15. Gastroenterol Res Pract. 2013. PMID: 23762038 Free PMC article.
-
Anti-Outer membrane protein C and anti-glycoprotein 2 antibodies in inflammatory bowel disease and their association with complicated forms of Crohn's disease.BMC Gastroenterol. 2014 Dec 31;14:190. doi: 10.1186/s12876-014-0190-1. BMC Gastroenterol. 2014. PMID: 25551469 Free PMC article.
-
Serum Biomarkers for Inflammatory Bowel Disease.Front Med (Lausanne). 2020 Apr 22;7:123. doi: 10.3389/fmed.2020.00123. eCollection 2020. Front Med (Lausanne). 2020. PMID: 32391365 Free PMC article. Review.
References
-
- Walker DG, Williams HR, Kane SP, Mawdsley JE, Arnold J, McNeil I, Thomas HJ, Teare JP, Hart AL, Pitcher MC, Walters JR, Marshall SE, Orchard TR. Differences in inflammatory bowel disease phenotype between South Asians and Northern Europeans living in North West London, UK. Am J Gastroenterol. 2011;106:1281–1289. doi: 10.1038/ajg.2011.85. - DOI - PubMed
-
- Bogdanos DP, Rigopoulou EI, Smyk DS, Roggenbuck D, Reinhold D, Forbes A, Laass MW, Conrad K. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn’s disease specific-pancreatic autoantibodies. Autoimmun Rev. 2011;11:143–148. doi: 10.1016/j.autrev.2011.09.004. - DOI - PubMed
-
- Wehkamp J, Koslowski M, Wang G, Stange EF. Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn’s disease. Mucosal Immunol. 2008;S1:67–74. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous